Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
7
×
boston blog main
boston top stories
7
×
life sciences
national blog main
clinical trials
national top stories
fda
deals
rare disease drugs
roche
san francisco blog main
alexion pharmaceuticals
avapritinib
blueprint medicines
dyne therapeutics
eli lilly
genentech
medullary thyroid cancer
myotonic dystrophy type 1
non-small cell lung cancer
pralsetinib
san diego blog main
san francisco top stories
selpercatinib
thyroid cancer
ally bridge group
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
astellas pharma
atlas venture
audentes therapeutics
autoimmune disorders
avidity biosciences
big data analytics
biotech ipos
blackrock
bluebird bio
boehringer ingelheim
What
drug
7
×
medicines
7
×
genetic
ipo
muscle
approval
blueprint
cancer
candidate
company
disease
diseases
dyne
fda
lead
million
pharma
pharmaceuticals
raised
rare
ret
roche
team
therapeutics
address
ago
alternative
analysis
approves
autoimmune
bio
biotech
biotechs
bring
brings
carries
caught
causing
certain
considering
Language
unset
Current search:
medicines
×
drug
×
boston
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma